Kali-Extracts Inc. Cannabis Pharmaceutical Value Highlighted In Goldman Small Cap Research Report

Kali Extracts

DALLAS, Jan. 09, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Kali, Inc. (dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today featured segments of the Goldman Small Cap Research Report published yesterday that highlight KALY’s cannabis pharmaceutical value:

“Prior to the acquisition by Kali-Extracts, NCM Biotech was engaged with a number of different universities on a number of separate research initiatives.  As an example, and as a preview of an upcoming announcement, NCM has been involved in an ongoing study with a university in Kentucky on the use of a cannabis therapy derived from Kali-Extracts’s patented extraction process for the treatment of Chronic Obstructive Pulmonary Disease (COPD). A paper on the results of the study using Kali-Extracts’s patented extraction process is anticipated to be published sometime this quarter. The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025. Thus, if the current preclinical study trajectory on the development side holds, the market opportunity is huge.”

“Separately, management believes that based on feedback from those that were involved in the aforementioned study that the Kali-Extracts extracts may be superior to those of GW Pharmaceuticals, the maker of Epidiolex. Plus …”

“We applaud the management team for engaging in an over-lapping, multi-pronged and staged approach to revenue generation. Clearly, near-term revenue is set to be driven by the wellness segment while the pharmaceutical side develops and could potentially be worth more than the wellness aspect of the overall business. Such valuations will be determined by future studies and trials. In the meantime, it appears that tangible, fairly consistent revenue streams are in the cards for KALY on the wellness side while favorable news on the pharmaceutical development front this quarter should be considered a strong milestone event. In our view, for investors interested in the hemp-based CBD industry, KALY bears watching, given its multiple shots on goal and broad-based potential.”

The report is available under “research” on the OTCMarkets website. The research report is the first report from Goldman Small Cap Research as part of an ongoing research engagement. The report outlines the company’s current positioning and potential, upcoming milestones. The report is intended to augment the current information available on the OTCMarkets website. KALY has recently updated all of its financial reports required by OTCMarkets to satisfy the OTCMarkets “current” filing standards and anticipates the OTCMarkets site to soon reflect Kali’s “current” filing status. As of the publication of this release, OTCMarkets has yet to update this status. All quotation information cited in the report was derived from Yahoo!Finance which reports Kali intraday trading activity and news. While quote information is not available on OTCMarkets website pending the filing status update, investors and shareholders can alternatively obtain current quote information on Yahoo!Finance or from their own online brokerage account.

The report is also available to read or download, along with associated disclosures and disclaimers, at www.GoldmanResearch.com.

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.

Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published report on Kali, Inc. The information provided in the report was for information use only and may have contained forward-looking statements along with statements of fact that may have been obtained from sources considered reliable. Thus, we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from press releases issued by and due diligence related to management of Kali, Inc. some of which are referred to in authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.

Separate from the factual content of our report, we may from time to time include our own opinions about the Companies, its business, markets and opportunities. Any opinions we may offer about the Companies are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein and in the report may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

It should be noted that Kali has recently updated all of its financial reports required by OTCMarkets to satisfy the OTCMarkets “current” filing standards and anticipates that the OTCMarkets site to soon reflect Kali’s “current” filing status. As of the report publication date, OTCMarkets has yet to update this status. All quotation information cited in the report was derived from Yahoo!Finance which reports Kali intraday trading activity and news.

A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, podcast interview or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only.  Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. To download or view the Kali report or any of our research on Puration, Inc., or other sponsored research, please view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com.

Goldman Small Cap Research was compensated $3500 by the Company for the publication of this report. It should be noted that during 2018, GSCR was compensated by Puration, Inc. in the amount of $5500 for a research subscription service and a previous podcast interview.

About Kali, Inc.  (OTC – KALY) Kali, Inc. is a health and wellness company set to generate revenue via licensing its patented cannabis extraction technology to multiple companies in the wellness and pharmaceutical industries. With promising preclinical data along with development and various commercial agreements behind it, Kali, Inc. seeks to commercialize its unique and valuable IP targeting multi-billion-dollar markets.

For more information, please visit: www.kali-extracts.com

Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com

Kali, Inc.
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459

MJ Canada

Related News